Inherited blood coagulation disorder
MONDO:0021181Hemorrhagic and thrombotic disorders that occur as a consequence of inherited abnormalities in blood coagulation.
Also known as: coagulation disorder, hereditary, coagulation disorder, inherited, coagulation disorders, hereditary, coagulation disorders, inherited, hereditary blood coagulation disease, hereditary blood coagulation disorders, hereditary coagulation disorder, hereditary coagulation disorders
326 clinical trials for this condition and its sub-types, 8 tagged with Inherited blood coagulation disorder itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Inherited blood coagulation disorder
-
Hemophilia A 180 trials
5 sub-types
- Severe hemophilia A 50 trials
- Moderately severe hemophilia A 4 trials
- Mild hemophilia A 2 trials
- Hemophilia A with vascular abnormality 0 trials
- Symptomatic form of hemophilia A in female carriers 0 trials
-
Hemophilia B 84 trials · 91 incl. sub-types
4 sub-types
- Severe hemophilia B 9 trials
- Moderately severe hemophilia B 2 trials
- Mild hemophilia B 1 trial
- Symptomatic form of hemophilia B in female carriers 0 trials
-
Hereditary von Willebrand disease 18 trials · 29 incl. sub-types
5 sub-types
- Von Willebrand disease 3 9 trials
- Von Willebrand disease 2 4 trials · 5 incl. sub-types Sub-types →
- Von Willebrand disease 1 3 trials
- Von Willebrand disease, X-linked form 0 trials
- Platelet-type von Willebrand disease 0 trials
-
Inherited thrombophilia 0 trials · 28 incl. sub-types
12 sub-types
- Thrombophilia due to thrombin defect 19 trials
- Thrombophilia due to activated protein C resistance 5 trials
- Hereditary antithrombin deficiency 3 trials
- Hereditary thrombophilia due to congenital protein C deficiency 1 trial Sub-types →
- Factor 5 excess with spontaneous thrombosis 0 trials
- Heparin cofactor 2 deficiency 0 trials
- Hereditary thrombophilia due to congenital histidine-rich (poly-L) glycoprotein deficiency 0 trials
- Hereditary thrombophilia due to congenital protein S deficiency 0 trials Sub-types →
- Thrombomodulin-related bleeding disorder 0 trials
- Thrombophilia, X-linked, due to factor 8 defect 0 trials
- Thrombophilia, X-linked, due to factor 9 defect 0 trials
- Thrombophilia, familial, due to decreased release of tissue plasminogen activator 0 trials
-
Hereditary hemolytic uremic syndrome 0 trials · 19 incl. sub-types
2 sub-types
-
Wiskott-Aldrich syndrome 10 trials
-
Glanzmann thrombasthenia 8 trials
2 sub-types
- Glanzmann thrombasthenia 1 7 trials
- Glanzmann thrombasthenia 2 0 trials
-
Platelet-type bleeding disorder 10 8 trials
-
Hereditary thrombocytopenia and hematologic cancer predisposition syndrome 1 trial · 5 incl. sub-types
2 sub-types
-
Hermansky-Pudlak syndrome 4 trials
9 sub-types
- Hermansky-Pudlak syndrome with pulmonary fibrosis 0 trials · 1 incl. sub-types Sub-types →
- Hermansky-Pudlak syndrome 10 0 trials
- Hermansky-Pudlak syndrome 11 0 trials
- Hermansky-Pudlak syndrome 2 0 trials
- Hermansky-Pudlak syndrome 7 0 trials
- Hermansky-Pudlak syndrome 8 0 trials
- Hermansky-Pudlak syndrome 9 0 trials
- Hermansky-Pudlak syndrome without pulmonary fibrosis 0 trials Sub-types →
- Kotzot-Richter syndrome 0 trials
-
Congenital vitamin K-dependent coagulation factors deficiency 0 trials · 4 incl. sub-types
5 sub-types
-
Congenital factor XII deficiency 1 trial
-
Hypoplasminogenemia 1 trial
-
Scott syndrome 0 trials
-
Tatsumi factor deficiency 0 trials
-
Alpha-2-plasmin inhibitor deficiency 0 trials
-
Congenital factor V deficiency 0 trials
-
Congenital factor XI deficiency 0 trials
-
Dysplasminogenemia 0 trials
-
Familial thrombomodulin anomalies 0 trials
-
Inherited prekallikrein deficiency 0 trials
-
Plasminogen deficiency, type II 0 trials
-
Platelet-type bleeding disorder 12 0 trials
-
Platelet-type bleeding disorder 14 0 trials
-
Platelet-type bleeding disorder 16 0 trials
-
Platelet-type bleeding disorder 18 0 trials
-
Platelet-type bleeding disorder 8 0 trials
Most studied deeper sub-types
-
Can a single gene shot free hemophilia b patients from regular infusions?
Cure Stopped earlyThis trial tests a gene therapy called FLT180a in adults with hemophilia B, a condition where the body lacks a clotting protein. The therapy delivers a working gene to help the body produce its own clotting factor. A small group of participants will receive a single dose and be f…
Phase 1/2 • Sponsor: Spur Therapeutics • Aim: Cure
Last updated Aug 02, 2026 00:00 UTC
-
Can a clotting boost make surgery safer for hemophilia patients?
Disease control Stopped earlyThis trial tests whether a medication called eptacog beta can safely prevent excessive bleeding in people with hemophilia A or B who have inhibitors and need major surgery. Participants receive the drug during and after their operation, and doctors measure how well bleeding is co…
Phase 3 • Sponsor: Laboratoire français de Fractionnement et de Biotechnologies • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Clotting drug may replace plasma transfusions in heart surgery
Disease control Stopped earlyThis study compared two treatments to reduce bleeding after heart valve surgery: a concentrated clotting drug (PCC) versus fresh frozen plasma (FFP). The trial planned to enroll 476 adults undergoing elective valve surgery. It was terminated early, so the full comparison was not …
Phase 4 • Sponsor: SHI Jia • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Gene-Edited cells aim to stop bleeding in severe hemophilia b
Disease control Stopped earlyThis early-stage trial tests a one-time treatment called BE-101 for adults with severe hemophilia B. The therapy uses a person's own blood cells, modified with CRISPR gene editing, to continuously produce the missing clotting factor. The goal is to reduce or prevent bleeding epis…
Phase 1/2 • Sponsor: Be Biopharma • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Hemophilia drug study falls short: only 3 patients enrolled before termination
Disease control Stopped earlyThis study aimed to see if a new medicine (efanesoctocog alfa) helps people with moderate or severe hemophilia A reach their personal goals and be more physically active. It planned to enroll 35 people aged 12 to 50, but was stopped early after only 3 joined. The medicine is used…
Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Promising aHUS drug trial stalls after only 6 patients enrolled
Disease control Stopped earlyThis study tested a drug called narsoplimab (OMS721) for atypical hemolytic uremic syndrome (aHUS), a rare condition that causes blood clots and organ damage. The trial aimed to see if the drug could improve platelet counts and was safe for adults and adolescents. However, the st…
Phase 3 • Sponsor: Omeros Corporation • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Cancer drug combo shows promise for Hard-to-Treat bowel cancer
Disease control Stopped earlyThis study tested a combination of two drugs, atezolizumab and bevacizumab, in 46 people with advanced colorectal cancer that had stopped responding to chemotherapy and had a specific genetic feature called MSI-like. The goal was to see if the treatment could shrink tumors. The s…
Phase 2 • Sponsor: Vall d'Hebron Institute of Oncology • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Gene Editing's lasting impact: a 10-Year safety watch
Knowledge-focused Stopped earlyThis study checks on people who previously received gene editing for hemophilia B or mucopolysaccharidosis (MPS) I or II. No new treatment is given; instead, participants are monitored for up to 10 years to see if any new health problems or worsening of existing conditions appear…
Sponsor: Sangamo Therapeutics • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
Could home blood tests transform hemophilia care? study seeks patient views
Knowledge-focused Stopped earlyThis study looked at how patients with hemophilia A or those on blood thinners feel about monitoring their blood clotting at home. Researchers interviewed 19 people to understand their needs and hopes for a new device that could measure clotting factors. The goal was to gather in…
Sponsor: Radboud University Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC